Molecular subtypes of pancreatic cancer
Cancers that appear morphologically similar often have dramatically different clinical
features, respond variably to therapy and have a range of outcomes. Compelling evidence …
features, respond variably to therapy and have a range of outcomes. Compelling evidence …
Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas
M Tanaka, C Fernández-del Castillo, T Kamisawa… - Pancreatology, 2017 - Elsevier
The management of intraductal papillary mucinous neoplasm (IPMN) continues to evolve. In
particular, the indications for resection of branch duct IPMN have changed from early …
particular, the indications for resection of branch duct IPMN have changed from early …
KRAS: the critical driver and therapeutic target for pancreatic cancer
RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated oncogene
family in human cancer. With the highest RAS mutation frequencies seen with the top three …
family in human cancer. With the highest RAS mutation frequencies seen with the top three …
A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas
International experts met to discuss recent advances and to revise the 2004
recommendations for assessing and reporting precursor lesions to invasive carcinomas of …
recommendations for assessing and reporting precursor lesions to invasive carcinomas of …
International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas
T Ohtsuka, C Fernandez-del Castillo, T Furukawa… - Pancreatology, 2023 - Elsevier
This study group aimed to revise the 2017 international consensus guidelines for the
management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas, and …
management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas, and …
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas
The international consensus guidelines for management of intraductal papillary mucinous
neoplasm and mucinous cystic neoplasm of the pancreas established in 2006 have …
neoplasm and mucinous cystic neoplasm of the pancreas established in 2006 have …
Pancreatic cancer
Substantial progress has been made in our understanding of the biology of pancreatic
cancer, and advances in patients' management have also taken place. Evidence is …
cancer, and advances in patients' management have also taken place. Evidence is …
[HTML][HTML] Artificial intelligence and early detection of pancreatic cancer: 2020 summative review
Despite considerable research efforts, pancreatic cancer is associated with a dire prognosis
and a 5-year survival rate of only 10%. Early symptoms of the disease are mostly …
and a 5-year survival rate of only 10%. Early symptoms of the disease are mostly …
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals
BACKGROUND & AIMS: The risk of pancreatic cancer is increased in patients with a strong
family history of pancreatic cancer or a predisposing germline mutation. Screening can …
family history of pancreatic cancer or a predisposing germline mutation. Screening can …
Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas
T Furukawa, Y Kuboki, E Tanji, S Yoshida, T Hatori… - Scientific reports, 2011 - nature.com
Intraductal papillary mucinous neoplasm (IPMN) is a common pancreatic cystic neoplasm
that is often invasive and metastatic, resulting in a poor prognosis. Few molecular alterations …
that is often invasive and metastatic, resulting in a poor prognosis. Few molecular alterations …